PL378418A1 - Zastosowanie karnityn w zapobieganiu i/lub leczeniu zaburzeń spowodowanych andropauzą - Google Patents

Zastosowanie karnityn w zapobieganiu i/lub leczeniu zaburzeń spowodowanych andropauzą

Info

Publication number
PL378418A1
PL378418A1 PL378418A PL37841803A PL378418A1 PL 378418 A1 PL378418 A1 PL 378418A1 PL 378418 A PL378418 A PL 378418A PL 37841803 A PL37841803 A PL 37841803A PL 378418 A1 PL378418 A1 PL 378418A1
Authority
PL
Poland
Prior art keywords
prevention
treatment
andropause
carnitines
disorders caused
Prior art date
Application number
PL378418A
Other languages
English (en)
Other versions
PL211032B1 (pl
Inventor
Aleardo Koverech
Giorgio Cavallini
Giulio Biagiotti
Original Assignee
Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. filed Critical Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Publication of PL378418A1 publication Critical patent/PL378418A1/pl
Publication of PL211032B1 publication Critical patent/PL211032B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Pregnancy & Childbirth (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL378418A 2002-12-13 2003-11-20 Zastosowanie propionylo-L-karnityny w zestawieniu z acetylo-L-karnityną lub ich farmaceutycznie dopuszczalnych soli do otrzymywania leku lub dodatku odżywczego PL211032B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000620A ITRM20020620A1 (it) 2002-12-13 2002-12-13 Uso delle carnitine per la prevenzione e/o il trattamento dei disturbi causati dall'andropausa.

Publications (2)

Publication Number Publication Date
PL378418A1 true PL378418A1 (pl) 2006-04-03
PL211032B1 PL211032B1 (pl) 2012-04-30

Family

ID=32587900

Family Applications (1)

Application Number Title Priority Date Filing Date
PL378418A PL211032B1 (pl) 2002-12-13 2003-11-20 Zastosowanie propionylo-L-karnityny w zestawieniu z acetylo-L-karnityną lub ich farmaceutycznie dopuszczalnych soli do otrzymywania leku lub dodatku odżywczego

Country Status (17)

Country Link
US (1) US7956091B2 (pl)
EP (1) EP1569635B1 (pl)
JP (1) JP4767542B2 (pl)
KR (1) KR101039818B1 (pl)
AT (1) ATE422883T1 (pl)
AU (1) AU2003288739A1 (pl)
CA (1) CA2507429C (pl)
CY (1) CY1109051T1 (pl)
DE (1) DE60326262D1 (pl)
DK (1) DK1569635T3 (pl)
ES (1) ES2322455T3 (pl)
IT (1) ITRM20020620A1 (pl)
MX (1) MXPA05006072A (pl)
PL (1) PL211032B1 (pl)
PT (1) PT1569635E (pl)
SI (1) SI1569635T1 (pl)
WO (1) WO2004054567A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407778B2 (en) 2002-02-07 2008-08-05 Pettegrew Jay W Compounds, compositions and methods for treating neuropsychiatric disorders
US20050272812A1 (en) * 2002-02-07 2005-12-08 Pettegrew Jay W Methor for use of acetyl-L-carnitine (ALCAR) for treatment of depressive disorders in humans
US7700074B2 (en) 2002-02-07 2010-04-20 Pettegrew Jay W Method and system for diagnosis of neuropsychiatric disorders including chronic alcoholism
DE602004022301D1 (de) 2003-05-29 2009-09-10 Jay W Pettegrew Glycerophosphocholin und derivate davon zur medizinischen abbildung von neuropsychiatrischen erkrankungen
ITRM20040561A1 (it) 2004-11-11 2005-02-11 Sigma Tau Ind Farmaceuti Uso della acetil l-carnitina in combinazione con propionil l-carnitina e sildenafil per il trattamento della disfunzione erettile.
KR101460125B1 (ko) * 2013-02-05 2014-11-11 주식회사 바이오그랜드 루이보스 추출물을 유효성분으로 하는 남성 노화 및 갱년기 예방 및 개선용 조성물
JP6483244B2 (ja) * 2015-04-17 2019-03-13 株式会社山田養蜂場本社 蜂の子を含有する滋養強壮剤

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3830931A (en) * 1972-11-06 1974-08-20 Felice S De Carnitine and its use in the treatment of arrhythmia and impaired cardiac function
IT1206954B (it) * 1979-02-12 1989-05-17 Sigma Tau Ind Farmaceuti Agenti terapeutici a base di un acil derivato della carnitina per la cura di vasculopatie periferiche
IT1116037B (it) * 1979-04-23 1986-02-10 Sigma Tau Ind Farmaceuti Esteri e ammidi di acil carnitine loro procedimenti di preparazione e loro uso terapeutico
IT1157238B (it) * 1982-10-29 1987-02-11 Sigma Tau Ind Farmaceuti Impiego di 1-carnitina per migliorare i paramenti biochimici e comportamentali dell'eta' senile
EP0681839A3 (en) 1994-05-12 1997-11-12 Hirohiko Kuratsune A pharmaceutical preparation comprising an acylcarnitine
IT1290801B1 (it) * 1996-07-05 1998-12-11 Mendes Srl Uso della acetil l-carnitina, della isovaleril l-carnitina, della propionil l-carnitina o dei loro sali farmacologicamente accettabili
IT1291127B1 (it) * 1997-04-01 1998-12-29 Sigma Tau Ind Farmaceuti Integratore alimentare per soggetti dediti ad intensa e prolungata attivita' fisica
IT1295408B1 (it) * 1997-10-03 1999-05-12 Sigma Tau Ind Farmaceuti Associazione di l-carnitina e alcanoil l-carnitine per il trattamento dell'alcoolismo
IT1302125B1 (it) * 1998-08-03 2000-07-31 Sigma Tau Healthscience Spa Composizione ad attivita' antiossidante ed antiproliferativacomprendente una carnitina ed un carotenoide
IT1302307B1 (it) * 1998-09-01 2000-09-05 Sigma Tau Healthscience Spa Composizione ad attivita' antiossidante ed atta a migliorarel'utilizzazione metabolica del glucosio, comprendente acetil
IT1306130B1 (it) * 1999-04-16 2001-05-30 Sigma Tau Healthscience Spa Composizione comprendente una carnitina e glutatione, atta adaumentare l'assorbimento del glutatione sinergizzandone gli effetti.
US6399116B1 (en) * 2000-04-28 2002-06-04 Rulin Xiu Rhodiola and used thereof
PL367628A1 (pl) * 2001-05-29 2005-03-07 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Zastosowanie alkanoilo L-karnityny do sporządzenia leku mającego zastosowanie w leczenia anhedonii

Also Published As

Publication number Publication date
PL211032B1 (pl) 2012-04-30
MXPA05006072A (es) 2005-09-30
KR20050084052A (ko) 2005-08-26
KR101039818B1 (ko) 2011-06-09
CA2507429A1 (en) 2004-07-01
DK1569635T3 (da) 2009-04-20
US20060135606A1 (en) 2006-06-22
SI1569635T1 (sl) 2009-06-30
EP1569635B1 (en) 2009-02-18
WO2004054567A1 (en) 2004-07-01
ATE422883T1 (de) 2009-03-15
ES2322455T3 (es) 2009-06-22
JP4767542B2 (ja) 2011-09-07
PT1569635E (pt) 2009-05-11
CY1109051T1 (el) 2014-07-02
US7956091B2 (en) 2011-06-07
JP2006511531A (ja) 2006-04-06
EP1569635A1 (en) 2005-09-07
CA2507429C (en) 2012-09-04
DE60326262D1 (de) 2009-04-02
AU2003288739A1 (en) 2004-07-09
ITRM20020620A1 (it) 2004-06-14

Similar Documents

Publication Publication Date Title
CA2341973A1 (en) Antioxidant composition comprising acetyl l-carnitine and .alpha.-lipoic acid
CY1109051T1 (el) Χρηση καρνιτινων για την προληψη και/ή θεραπεια διαταραχων που προκαλουνται απο την ανδροπαυση
FI3457135T3 (fi) Fabryn taudin hoitovaihtoehtoja
NZ593199A (en) Milnacipran for the long-term treatment of fybromyalgia syndrome
MXPA05003732A (es) Metodos y composiciones para proporcionar glutamina.
CY1111273T1 (el) Συνδυασμενη χρηση της l-καρνιτινης, ακετυλο l-καρνιτινης και προπιονυλο l-καρνιτινης για τη θεραπεια της ολιγοασθενοτερατοσπερμιας
IT1295408B1 (it) Associazione di l-carnitina e alcanoil l-carnitine per il trattamento dell'alcoolismo
AR021172A1 (es) Composicion antiprolifica, antioxidante, que comprende una carnitina y un carotenoide
SG162836A1 (en) Use of a combination comprising l-carnitine or alkanoyl l-carnitine, lipid solubl benzoquinone and omega-3-polyunsaturated fatty acid for the preparation of a dietary supplement or medicament for the treatment of corneal diseases
PL378537A1 (pl) Zastosowanie propionylo L-karnityny do otrzymywania leku do leczenia glaukomii
PT1534296E (pt) UTILIZAÇÃO DE CILOBRADINA OU DOS SEUS SAIS FARMACEUTICAMENTE ACEITÁVEIS PARA O TRATAMENTO OU PREVENÇÃO DA INSUFICIjNCIA CARDÍACA
AR024981A1 (es) Composicion para la prevencion y el tratamiento de las disfunciones y enfermedades del rinon
SI1824472T1 (sl) Uporaba acetil-l-karnitina za zdravljenje fibromialgiäśnega sindroma
SI1937245T1 (sl) Spojina uporabna za preprečevanje in zdravljenjeleve ventrikularne hipertofije pri dializiranih pacientih
WO2001064203A3 (en) Composition for the prevention and/or treatment of vascular diseases, comprising propionyl l-carnitine and coenzyme q¿10?
PL367616A1 (pl) Zastosowanie acetylo-L-karnityny do otrzymywania leku do terapii przeciwbólowej
IL164763A0 (en) Byperforin derivatives, the use thereof and formulations containing them
TW200420560A (en) Crystalline form
WO2008058993A3 (en) Use of alpha ketogluaric acid for the treatment of infection with h. pylori
NZ508292A (en) Treatment of migraine symptoms with ibuprofen and salts thereof
RU2002124697A (ru) Биологически активная добавка "мумивит"
RU2002120354A (ru) Биологически активная добавка "мумивит с витамином "с"
AU2002258182A1 (en) Use of acetyl l-carnitine for the preparation of a medication for the preventive therapy for pain
RU2002125553A (ru) Способ профилактики и лечения гепатодистрофии поросят